SB
NGNE icon

Samsara BioCapital’s Neurogene NGNE Stock Holding History

Samsara BioCapital’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$34.6M Hold
1,717,127
– – 3.36% 7
2025
Q4 		$35.4M Hold
1,717,127
– – 3.65% 6
2025
Q3 		$29.8M Hold
1,717,127
– – 3.89% 5
2025
Q2 		$25.7M Hold
1,717,127
– – 5.25% 5
2025
Q1 		$20.1M Hold
1,717,127
– – 3.59% 4
2024
Q4 		$39.3M Buy
1,717,127
+449,337
+35% +$16.7M 5.39% 5
2024
Q3 		$53.2M Hold
1,267,790
– – 10.22% 4
2024
Q2 		$46.1M Hold
1,267,790
– – 9.66% 4
2024
Q1 		$64.5M Hold
1,267,790
– – 9.98% 4
2023
Q4 		$24.6M Buy
+1,267,790
New +$18.2M 3.82% 6

Other funds holding NGNE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Samsara BioCapital's NGNE Position: Q1 2026 in Review

Samsara BioCapital held its Neurogene (NGNE) position steady in Q1 2026 at 1,717,127 shares worth $34.6M. The position accounts for 3.36% of the portfolio, ranked #7.

Samsara BioCapital first reported a position in NGNE in Q4 2023 and has held it in 10 quarters since. The position peaked at $64.5M in Q1 2024. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

  • Samsara BioCapital held 1,717,127 shares of Neurogene worth $34.6M as of Q1 2026.
  • Samsara BioCapital left its Neurogene share count unchanged in Q1 2026.
  • Neurogene made up 3.36% of Samsara BioCapital's portfolio in Q1 2026, its #7 holding.
  • Samsara BioCapital first reported a position in Neurogene in Q4 2023 and has held it in 10 quarters since.
  • Samsara BioCapital's Neurogene position peaked at $64.5M in Q1 2024.
  • 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on Samsara BioCapital's 13F filing for Q1 2026, filed 15 May 2026.